Exactly what you need,
for the care they deserve.

The MyRisk® Hereditary Cancer Test delivers actionable insights and end-to-end support that works for you.

Myriad Oncology

Each step. Every patient. Exactly what you need.

Exactly what you need, for the care they deserve.

The MyRisk® Hereditary Cancer Test delivers actionable insights and end-to-end support that works for you.

A complete solution for breast cancer risk assessment and management.

​With industry-leading variant classification,1 personalized risk insights, and streamlined workflows, the MyRisk® Hereditary Cancer Test supports your efforts in breast cancer risk assessment, early detection and treatment. From streamlined ordering within your EMR to patient education and clinical decision-making, Myriad Oncology™ provides the tools and insights you need to deliver confident, proactive care—every step of the way.

SPEAK WITH OUR TEAM ABOUT INTEGRATING THE MYRISK TEST INTO YOUR CLINIC’S WORKFLOW AND BREAST CANCER RISK ASSESSMENT PROGRAM

Get started with Myriad Oncology

Request more information about how Myriad’s Oncology solutions can benefit you/your patients.


Don't know your NPI? Click Here

By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.

Hidden Fields











Hidden test fields

Contact Information

Why Breast Surgeons choose the MyRisk Test.​

It is built for busy clinics and backed by a full support team.

  • Fast, low-burden ordering via paper Test Requisition Form (TRF), portal, or EMR system​
  • Results in ~14 days, or 7 days with STAT priority results for patients diagnosed with breast cancer​
  • A majority of patients face no out-of-pocket costs2
  • Pre- and post-test patient education provided by board-certified Genetic Counselors​
  • Myriad Medical Science Liaisons available for technical and clinical questions

Myriad Oncology™ helps you implement a Breast Cancer Risk Assessment program into your practice

  • Full rollout coordination, staff training, operational support​
  • Patient-first resources and patient education by our board-certified genetic counselors—at no extra cost
Get in touch

Beyond genes, the MyRisk Hereditary Cancer Test with RiskScore® empowers you with a full view of breast cancer risk

The MyRisk Test with RiskScore combines genetics, clinical factors, and polygenic risk to see what analyzing genes alone can’t, helping you to make more informed decisions in breast cancer risk assessment and management.

RiskScore is two times more predictive of breast cancer risk than Tyrer-Cuzick alone3

Predictive accuracy of RiskScore vs Tyrer-Cuzick alone

The MyRisk Test with RiskScore
uncovers hidden risk

MORE THAN
50%

a graphic representing 50% of people

of patients who test negative for a hereditary cancer syndrome have a change in medical management due to their family history of cancer and/or their RiskScore4

view ordering options to start using riskscore

When others say “uncertain,” the MyRisk Test gives you answers.

The MyRisk Test offers superior baseline DNA analysis and strategic RNA testing when appropriate—at no additional cost, often without the need for a re-draw5-7

  • Lowest reported rates of variants of uncertain significance (VUS) forBRCA1 (0.3%) andBRCA2 (0.7%)1​
  • Definitively classifies up to 63% of variants other labs can’t​8
  • Includes a Lifetime Classification Commitment to send amended reports if a VUS is reclassified as clinically significant

VUS rates for key breast cancer genes

Table showing the progression of VUS rates for key breast cancer genes from 2016 - 2023

Actionable genes only. That’s the MyRisk Test standard.

The MyRisk Test is expanding to include 15 additional clinically actionable genes based on national oncology guidelines — further empowering healthcare providers to personalize care plans and help guide preventive treatment decisions.9-11 This update will bring the panel to include all 13 breast cancer susceptibility genes recommended by ASCO.10,12

BE THE FIRST TO KNOW

More resources

See all resources
References
  1. Mundt E, McGreevy K, Nix P, Cummings S. Myriad's Multidisciplinary Approach and Consistent Investment in Variant Classification for Clinical Decision Making [White paper]. Myriad Genetics. 2025.
  2. Internal data on file at Myriad Genetics, Inc. Based on a review of 12 months of past claim data for major insurance carriers across the US, the majority of patients face no out-of-pocket costs for their MyRisk® test. Last updated 2024.
  3. Mabey B, Hughes E, Kucera M, et al. Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors. Genet Med. 2024;26(7):101128.
  4. Myriad internal data based on MyRisk tests reported between 09/01/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.
  5. Kamps-Hughes N, Carlton VEH, Fresard L, et al. A Systematic Method for Detecting Abnormal mRNA Splicing and Assessing Its Clinical Impact in Individuals Undergoing Genetic Testing for Hereditary Cancer Syndromes. J Mol Diagn. 2023;25(3):156-167
  6. Nix P, Mundt E, Manley S, Coffee B, Roa B. Functional RNA Studies Are a Useful Tool in Variant Classification but Must Be Used With Caution: A Case Study of One BRCA2 Variant. JCO Precis Oncol. 2020;4:730-735.
  7. Nix P, Mundt E, Cummings SA, Roa B, Enhancing variant interpretation in hereditary cancer testing with RNA analysis from residual blood samples. J Clin Oncol. 2025;43(16_suppl):e22595
  8. Gradishar W, Johnson K, Brown K, et al. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. Oncologist. 2017;22(7):797-803.
  9. Internal product development data on file at Myriad Genetics, Inc. Last updated 2025.
  10. Tung N, Ricker C, Messersmith H, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;42(21):2599-2615
  11. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines.) Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. V1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed September 4, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  12. Bedrosian I, Somerfield MR, Achatz MI, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol. 2024;42(5):584-604

Locations

United States
Europe
Japan